We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Celularity Inc | NASDAQ:CELU | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.43% | 2.32 | 2.00 | 2.44 | 2.40 | 2.28 | 2.33 | 111,224 | 23:55:00 |
From Jul 2024 to Jan 2025
H.C. Wainwright 26th Annual Global Investment ConferenceDate: Monday, September 9, 2024Time: 12:30 p.m. ET Location: Lotte New York Palace Hotel, New YorkSpeaker: Robert J. Hariri, M.D., Ph.D., Founder, Chairman & CEO
Celularity will also participate in one-on-one investor meetings at the conference. To obtain more information on the conference, or schedule an investor meeting with Dr. Hariri, please contact your H.C. Wainwright representative or KCSA Strategic Communications at Celularity@KCSA.com.
A replay of this presentation will be available on the Company's website at https://celularity.com/investor-relations/ for at least 90 days following the date of the presentation.
About Celularity
Celularity Inc. (NASDAQ: CELU) is an innovative regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. What sets Celularity apart is its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Celularity’s unique approach, harnessing the placenta’s biology and ready availability, is paving the way for therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Carlos RamirezSenior Vice President, Celularity Inc.Carlos.ramirez@celularity.com
Raquel Cona / Michaela FawcettKCSA Strategic Communicationsrcona@kcsa.com / mfawcett@kcsa.com
1 Year Celularity Chart |
1 Month Celularity Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
